Search Results 11-20 of 16548 for ������������KA���:ZA31���24������ ���������������������������������

  1. Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Systemic Sclerosis - Mayo Clinic

    Serum creatinine must be stable (with no increases ≥ 20%) for a minimum of 24 weeks post-renal crisis at the time of the screening visit. Cardiac ...

  2. Mayo Clinic

    Determine the preexisting and therapy-emergent germline and somatic variants associated with an increased risk of clonal and non-clonal cytopenia following CAR- ...

  3. Uterine fibroids - Doctors and departments - Mayo Clinic

    Learn about these common noncancerous growths and what to do if you have symptoms such as heavy menstrual bleeding.

  4. Holter monitor - Mayo Clinic

    Accessed Jan. 24, 2022. AskMayoExpert. Ambulatory heart rhythm monitoring. Mayo Clinic; 2021. Medical review (expert opinion). Mayo Clinic. Dec. 5, 2018.

  5. 24/7 support - Mayo Clinic

    The Nicotine Dependence Center's eight-day residential treatment program is staffed 24 hours a day. Experienced support staff members are present in the ...

  6. CY 6031 Study Will Evaluate the Effects of Treatment With Aficamten (CK-3773274) Over a 24-week Period on Cardiopulmonary Exercise Capacity and Health Status in Patients With Symptomatic oHCM - Mayo Clinic

    CY 6031 Study Will Evaluate the Effects of Treatment With Aficamten (CK-3773274) Over a 24-week Period on Cardiopulmonary Exercise Capacity and Health Status in ...

  7. Publications - Kendall K. Tasche, M.D. - Mayo Clinic

    2025 Jun 1; 46 (5):e198-e201 Epub 2025 Feb 24 ... KA, McGarrah PW, Fuentes Bayne HE, Routman DM ... 2023 Mar-Apr; 44 (2):103806 Epub 2023 Feb 24. View ...

  8. Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors - Mayo Clinic

    PRI-724 dosing is to start at 40 mg/m2/day, CIV infusion over 24 hours × 7 days. Phase Ib: This phase is to begin upon identification of the MTD in Phase 1a ...

  9. A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors - Mayo Clinic

    Sponsor Protocol Number: CGT4859-24-101. About this study. This is an open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetic (what ...

  10. OHF Patient Registry - Mayo Clinic

    Rochester, Minnesota: 24-007676. About this study. The purpose of this study is that the Oxalosis and Hyperoxaluria Foundation (OHF) Registry in collaboration ...